CSL News

New National Fractionation Agreement

CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian go…

Expansion of CSL Biotech Facility

CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows wit…

CSL and Vitaeris Strategic Partnership

Agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid or…

CSL112 Phase 3 Clinical Trial

The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 site…

Australian Scientists Awarded $2.5m

Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research…

Applications Open for CSL Centenary Fellowship Program

Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million ov…

New Therapy for Diabetic Kidney Disease

An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the prog…

Momenta and CSL Announce Collaboration

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered in…